ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
U.S. Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is August 27, 2025. Off-label repackaged bevacizumab is one of the most frequently used first-line anti-VEGF treatments in Europe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results